Prostate Cancer

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

The use of denosumab to prevent SREs in men with mCRPC has questionable cost-effectiveness as compared with zoledronic acid.

A pivotal phase III study found that men with CRPC experienced prolonged bone metastasis–free survival with Xgeva versus placebo.

New findings suggest that long-term, regular acetaminophen use may be associated with a lower risk of prostate cancer.

Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test

Donna Berry on the Challenges Patients With Prostate Cancer Face

Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

A search for potential chemopreventive agents for prostate cancer uncovered an unlikely candidate in digoxin, one of the oldest drugs for cardiovascular disorders

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized, high-risk prostate cancer patients

Immunotherapies made headlines in oncology last month when the Centers for Medicare & Medicaid Services (CMS) decided that the anticancer vaccine sipuleucel-T (Provenge) will be a payable expense for prostate cancer.

Screening for prostate cancer does work, despite controversy about its efficacy

Therapies that target bone metastases have been developed for more than a decade.

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

Increased prostate cancer screening has led to overtreatment and has not significantly reduced mortality rates in prostate cancer.

PROSTVAC-VF uses the smallpox viral vector to stimulate the immune system.

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

New data show that most prostate cancer patients who receive androgen-deprivation therapy gain a significant amount of weight within a year of starting treatment

Many clinicians are not employing radiation therapy used in combination with androgen deprivation therapy even though guidelines suggest they should

New data suggested that hospitals that purchase a surgical robot experience a subsequent hike in the number of radical prostatectomies